17-alpha-hydroxyprogesterone

17-al·pha-hy·drox·y·pro·ges·ter·one

(-ăl′fə-hī-drŏk′sē-prō-jĕs′tə-rōn′)
n.
A compound produced by the adrenal glands and often used therapeutically as a progestogen when such a steroid is needed for parenteral administration.
References in periodicals archive ?
For women who had a prior preterm birth, cervical cerclage was offered, as well as vaginal progesterone if the patient was not already on 17-alpha-hydroxyprogesterone caproate.
What we have learned about the role of 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth.
Cervical length changes during preterm cervical ripening: effects of 17-alpha-hydroxyprogesterone caproate.
The Food and Drug Administration has approved 17-alpha-hydroxyprogesterone caproate, a progesterone injection also known as 17P, for the prevention of recurrent preterm birth in women with singleton pregnancies.
He pinpointed Takeover Target because of his ban for failing a test for 17-alpha-hydroxyprogesterone hexanoate, or HPC, a steroid that can build muscle.
The new treatment, weekly shots of a hormone called 17-alpha-hydroxyprogesterone caproate, or 17P, were started at sixteen to eighteen weeks of pregnancy and stopped at thirty-six weeks.
Food and Drug Administration ("FDA") issued an approvable letter to Adeza Biomedical for their candidate for prevention of recurrent preterm birth, the synthetic progestogen 17-alpha-hydroxyprogesterone caproate (trademarked "Gestiva").
In this case, the FDA had approved a compounded therapy 17-alpha-hydroxyprogesterone caproate (17P) to prevent preterm birth.
This randomized trial of 69 women who experienced preterm premature rupture of membranes (PPROM) at 20 to 30 weeks' gestation found no difference in the length of gestation between women given 250 mg of 17-alpha-hydroxyprogesterone (17P) or placebo weekly.
Food and Drug Administration ("FDA") has issued an approvable letter to Adeza Biomedical for their synthetic progestogen, 17-alpha-hydroxyprogesterone caproate (trademarked "Gestiva"), Adeza's candidate for prevention of recurrent preterm birth.
CHICAGO -- The effect of 17-alpha-hydroxyprogesterone caproate on preterm birth varies depending on the presence or absence of cerclage in high-risk women, according to a planned secondary analysis of the Vaginal Ultrasound Cerclage Trial.
HONG KONG The Hong Kong Jockey Club yesterday announced that independent analysis of a blood sample taken from top Australian sprinter Takeover Target had confirmed the presence of locally banned substance 17-alpha-hydroxyprogesterone hexanoate, writes Jon Lees.